Ann: Optiscan Completes Cloud-based Telepathology Software MVP, page-3

Given the high value proposition, especially for specialized procedures like cancer surgery and the potential for cost savings, clinics would likely accept a SaaS model with a mix of tiered subscriptions and usage-based components.

Small to Medium Clinics/Standalone Surgical Centers: Might pay a few hundred to a couple of thousand Australian Dollars (AUD) per month for a basic subscription covering a limited number of users/sessions, focusing on immediate diagnostic needs. This would be attractive for its efficiency gains and improved patient care.

Larger Hospitals/Hospital Networks with Multiple Sites: These institutions would see significant value in enterprise-level subscriptions. They might be willing to pay anywhere from AUD $5,000 to $20,000+ per month, depending on the number of integrated devices, concurrent users, data storage needs, and premium features (e.g., advanced analytics, dedicated support). The value here lies in system-wide efficiency, leveraging existing staff across different locations, and expanding access to expertise.

Specialty Clinics (e.g., Oral Surgery, Breast Cancer Centers): For highly specialized use cases where the technology directly impacts surgical precision and reduces re-excision rates, the perceived value would be higher. They might pay a premium for features directly linked to these critical outcomes.

Overall: The willingness to pay will be heavily influenced by how effectively Optiscan can demonstrate quantifiable ROI (Return on Investment) through case studies showcasing reduced OR time, fewer repeat surgeries, and improved diagnostic accuracy leading to better patient outcomes. The "game-changer" aspect for regional and remote healthcare also opens up potential for government funding or subsidies, which could further drive adoption.